Breast MR imaging screening in 192 women proved or suspected to be carrier of a breast cancer susceptibility gene: Preliminary results

Radiology

Volumn 215, Issue 1, 2000, Pages 267-279

  Kuhl, Christiane Katharina ^a   Schmutzler, Rita K ^a   Leutner, Claudia Christiane ^a   Kempe, Andrea ^a   Wardelmann, Eva ^a   Hocke, Andrea ^a   Maringa, Monika ^a   Pfeifer, Ulrich ^a   Krebs, Dieter ^a   Schild, Hans Heinz ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Breast neoplasms, diagnosis; Breast neoplasms, MR; Breast neoplasms, radiography; Breast neoplasms, US; Breast, MR; Cancer screening; Genes and genetics

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ECHOMAMMOGRAPHY; FEMALE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0034125482     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.215.1.r00ap01267     Document Type: Article

References (58)

1. National Cancer Institute. SEER cancer statistics review, 1973-1995: section 4 - breast. Female breast cancer: trends in SEER incidence and U.S. mortality. Available at: http://www-seer.ims.nci.nih.gov/ Publications/CSR7395/breast.pdf. Accessed February 2, 2000.
2. Lynch HT, Albano WA, Danes BS, et al. Genetic predisposition to breast cancer. Cancer 1984; 53:612-622.
3. Chang-Claude J, Becher H, Hamann U, Schröder KT. Risikoabschätzung für das familiäre auftreten von brustkrebs. Zentralbl Gynakol 1995; 117:423-434.
4. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
5. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792.
6. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997; 60:1013-1020.
7. Serova O, Mazoyer S, Puget N, et al. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer susceptibility genes? Am J Hum Genet 1997; 60:486-495.
8. King MC, Rowell S, Love S. Inherited breast and ovarian cancer: what are the risks? What are the choices? JAMA 1993; 269:1975-1980.
9. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer. JAMA 1995; 273:577-585.
10. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77:2318-2324.
11. Easton DF, Bishop DT, Ford D, Crockford GP, and the Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993; 52:678-701.
12. Peer PG, Verbeek AL, Straatman H, HendriksJH, Holland R. Age-specific sensitivities of mammographic screening for breast cancer. Breast Cancer Res Treat 1996; 38: 153-160.
13. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography: a meta-analysis. JAMA 1995; 273:149-154.
14. de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 1995; 87:1217-1223.
15. van Gils CH, Otten JD, Verbeek AL, Hendriks JH, Holland R. Effect of mammographic breast density on breast cancer screening performance: a study in Nijmegen, the Netherlands. J Epidemiol Community Health 1998; 52:267-271.
16. Meyer JE, Kopans DB, Oot R. Breast cancer visualized by mammography in patients under 35. Radiology 1983; 147:93-94.
17. Swedish Cancer Society and the Swedish National Board of Health and Welfare. Breast-cancer screening with mammography in women aged 40-49 years. Int J Cancer 1996; 68:693-699.
18. Hendrick RE, Smith RA, Rutledge JH III, Smart CR. Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr 1997; 22:87-92.
19. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997; 386:804-810.
20. Bebb G, Glickman B, Gelmon K, Gatti R. "At risk" for breast cancer. Lancet 1997; 349(9068):1784-1785.
21. Vaidya JS, Baum M. Benefits and risks of screening mammography in women with BRCA1 and BRCA2 mutations (letter). JAMA 1997; 278:289-290.
22. Lynch HT, Watson P. Mammography and hereditary breast cancer (letter). Breast Cancer Res Treat 1990; 15:53.
23. Den-Otter W, Merchant TE, Beijerinck D, Koten JW. Breast cancer induction due to mammography screening in hereditarily affected women. Anticancer Res 1996; 16:3173-3175.
24. Sluijter FJ, Koten JW, Den Otter W. Hereditary breast cancer and possible risk of mammography (letter). Breast Cancer Res Treat 1989; 13:277.
25. Beemsterboer PM, Warmerdam PG, Boer R, de Koning HJ. Radiation risk of mam-mography related to benefit in screening programmes: a favourable balance? J Med Screen 1998; 5:81-87.
26. Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA - preliminary observations. Radiology 1989; 170:681-686.
27. Heywang SH. Contrast enhanced magnetic resonance imaging of the breast. Invest Radiol 1994; 29:94-104.
28. Fischer U, Vosshenrich R, Probst A, Burchhardt H, Grabbe E. Präoperative MR-mammographie bei bekanntem mammakarzinom: sinnvolle mehrinformation oder sinnloser mehraufwand? Rofo Fortschr Geh Rontgenstr Neuen Bildgeb Verfahr 1994; 161:300-306.
29. Harms SE, Flamig DP. MRI of the breast. J Magn Reson Imaging 1993; 3:277-283.
30. Orel SG, Schnall MD, Powell CM, et al. Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology 1995; 196:115-122.
31. Gilles R, Guinbretière JM, Lucidarme O, et al. Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MRI. Radiology 1994; 191:625-631.
32. Weinreb JC, Newstead G. MR imaging of the breast. Radiology 1995; 196:593-610.
33. Schorn C, Fischer U, Luftner-Nagel S, Westerhof JP, Grabbe E. MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol 1999; 9:470-473.
34. Kuhl CK, Kreft BP, Bieling HB, et al. Dynamic breast MRI in premenopausal healthy volunteers: normal values of contrast enhancement and cycle phase dependency. Radiology 1997; 203:137-144.
35. Kuhl CK, Sommer T, Gieseke J, Schild HH. Fokale und diffuse läsionen in der dynamischen MR-mammographie gesunder probandinnen. Fortschr Röntgenstr 1995; 163:195-282.
36. Müller-Schimpfle M, Ohmenhauser K, Stoll P, Dietz K, Claussen CD. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997; 203:145-149.
37. Rosenblum BB, Lee LG, Spurgeon SL, et al. New dye-labeled terminators for improved DNA sequencing patterns. Nucleic Acids Res 1997; 25:4500-4504.
38. Helvie MA, Roubidoux MA, Weber BL, Merajver SD. Mammography of breast carcinoma in women who have mutations of the breast cancer gene BRCA1: initial experience. AJR Am J Roentgenol 1997; 168:1599-1602.
39. American College of Radiology (ACR). Reporting system. In: Breast imaging reporting and data system (BI-RADS). 2nd ed. Reston, Va: American College of Radiology, 1995; 15-18.
40. Kolb TM, Lichy J, Newhouse JH. Occult cancer in women with dense breasts: detection with screening US - diagnostic yield and tumor characteristics. Radiology 1998; 207:191-199.
41. Kuhl CK, Mielcarek P, Klaschik S, et al. Are signal time course data useful for differential diagnosis of enhancing lesions in dynamic breast MR imaging? Radiology 1999; 211:101-110.
42. Kuhl CK, Elevelt A, Leutner C, et al. Clinical use of a stereotaxic biopsy device for MR-guided intervention of suspicious breast lesions. Radiology 1997; 204:667-675.
43. Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1 induced breast and ovarian cancer. Eur J Cancer 1997; 33:362-371.
44. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998; 16:397-404.
45. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349:1505-1510.
46. Foulkes WD, Wong N, Brunet JS, et al. Germline BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997; 3:2456-2469.
47. Foulkes WD, Wong N, Rozen F, Brunet JS, Narod SA. Survival of patients with breast cancer and BRCA1 mutations. Lancet 1998; 351:1359-1360.
48. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84.
49. Ponder B. Genetic testing for cancer risk. Science 1997; 278:1050.
50. Decker D. Prophylactic mastectomy for familial breast cancer. JAMA 1993; 269: 2608-2609.
51. Klijn JG, Janin N, Cortes-Funes H, Colomer R. Should prophylactic surgery be used in women with a high risk of breast cancer? Eur J Cancer 1997; 33:2149-2159.
52. Goodnight JE Jr, Quagliana JM, Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 1984; 26:198-201.
53. Willemsen HW, Kaas R, Peterse JH, Rutgers EJ. Breast carcinoma in residual breast tissue after prophylactic bilateral subcutaneous mastectomy. Eur J Surg Oncol 1998; 24:331-332.
54. Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998; 83:2335-2345.
55. Lakhani SR, Jacquemire J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90:1138-1145.
56. Eisinger F, Jacquemier J, Charpin C, et al. Mutations at BRCA1: the medullary breast cancer revisited. Cancer Res 1998; 58: 1588-1592.
57. Porter DE, Dixon M, Smyth E, Steel CM. Breast cancer survival in BRCA1 carriers. Lancet 1993; 341:184-185.
58. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351: 316-321.